In the News

• 06.13.2025  |  AMR: Fixing the broken pipeline for new antibiotics

  OPEN ACCESS GOVERNMENT | Melissa Gong Mitchell, the Secretariat Lead at the AMR Industry Alliance, discusses the challenges hindering the development of urgently needed new antibiotics and the sustainable solutions needed to address these issues.

  Full Story

• 05.13.2025  |  Bridging global expertise with South Australia’s ingenuity to tackle antimicrobial resistance

  MTPCONNECT | Ahead of the Australian Society for Microbiology Annual National Meeting (14-17 July) in Adelaide, we will be hosting an exclusive discussion with leading experts to uncover the myths surrounding innovation and commercialisation in the fight against antimicrobial resistance (AMR).

  Full Story

• 04.16.2025  |  Taking the Australian AMR story to ESCMID Global Congress in Vienna

  MTPCONNECT | This week around 15,000 – 20,000 delegates have converged on Austria’s capital, Vienna, for the 2025 ESCMID Global Congress - the largest conference of its kind, to focus on the latest in infectious diseases and clinical microbiology, and MTPConnect's AMR initiative, the Australian Antimicrobial Resistance Network (AAMRNet) is there.

  Full Story

• 04.15.2025  |  Antimicrobial resistance: Q&A with CARB-X about the fight against AMR

  EUROPEAN BIOTECHNOLOGY | n issue 1-25 of European Biotechnology News Magazine, we featured the ‘pandemic crossroads’ of pandemic (viral) infections and the silent pandemy of antimicrobial resistance which raises from animal farming and may help crossing the barrier of species for viruses. EBM talked to CARB-X Executive Director Kevin Outterson.

  Full Story

• 03.28.2025  |  Innovazione e prevenzione. Così si investe sulla salute del domani

  FORMICHE | Prevenzione, innovazione, ricerca: questi i temi al centro del confronto tra esperti e istituzioni sul palco del Centro studi americani.

  Full Story

• 02.26.2025  |  CARB-X announces new round of funding for antibiotics, diagnostics

  CIDRAP | CARB-X today announced a new round of funding targeting therapeutics for gram-negative bacterial infections and rapid diagnostics for typhoid fever.

  Full Story

• 02.07.2025  |  BioInfect 2025 sees a great turnout for a day of AMR discussion

  BIOINFECT | BioInfect returned to The Spine in Liverpool for the second year in a row on 5th February, with over 175 delegates, 14 exhibitors and 15 poster abstracts focusing on the issues surrounding the increasing threat of AMR and how it can be addressed.

  Full Story

• 01.30.2025  |  Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year

  NOVO NORDISK FOUNDATION | In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving people’s health and the sustainability of society and the planet.

  Full Story

• 01.27.2025  |  Health experts, academics, business leaders and local students will take centre stage at antimicrobial resistance conference as BioInfect returns to Liverpool

  BIONOW | Health experts, academics, business leaders and local students will take centre stage at antimicrobial resistance conference as BioInfect returns to Liverpool.

  Full Story

• 01.24.2025  |  Muschel (Hera): “In Ue 35mila morti all’anno dovuti all’Amr, la ricerca priorità assoluta”

  RIF DAY | Sono cifre da bollettino di guerra: la resistenza agli antibiotici in Europa provoca 35mila decessi all’anno.

  Full Story

• 01.24.2025  |  Ministro Schillaci a Davos: ribadito l’impegno a contrastare la piaga della resistenza agli antibiotici

  MONDOSANITA | La nostra salute sotto i riflettori in occasione del World Economic Forum di Davos, un evento annuale che riunisce statisti, leader politici, rappresentanti del mondo economico e della società civile.

  Full Story

• 01.22.2025  |  Four opportunities to revitalize the US biomedical research enterprise

  HEALTH AFFAIRS | The US biomedical research enterprise is renowned for its historical and ongoing scientific breakthroughs and advancements.

  Full Story

• 01.21.2025  |  CARB-X funds $3.5M to Melio for rapid neonatal sepsis diagnostic

  CONTAGION LIVE | CARB-X has awarded a $3.5 million grant to Melio, a biotechnology company, to develop a rapid diagnostic tool to detect neonatal sepsis.

  Full Story

• 01.13.2025  |  How the Global AMR Innovation Fund is leading the fight against antimicrobial resistance

  INNOVATION NEWS NETWORK | In a world increasingly shaped by scientific advancements, one of the most pressing challenges is antimicrobial resistance (AMR)—a growing threat to global health, economies, and future generations.

  Full Story

• 01.13.2025  |  Collaborative innovation: Reimagining R&D partnerships to create a healthier future for everyone

  WORLD ECONOMIC FORUM | Reinventing private, public and philanthropic collaboration could help develop multi-faceted solutions targeting infectious disease, mental health and the health impacts of climate change.

  Full Story

• 01.07.2025  |  $2.6 million accelerates anti-biofilm vaccine to prevent bacterial infections

  VAX BEFORE TRAVEL | CARB-X today announced it awarded Clarametyx Biosciences $2.6 million to develop an anti-biofilm vaccine.

  Full Story

• 01.07.2025  |  CARB-X funds development of anti-biofilm vaccine

  CIDRAP | CARB-X today announced an award of $2.6 million to Clarametyx Biosciences to develop an anti-biofilm vaccine.

  Full Story

• 01.03.2025  |  Mit „sportlichem Ehrgeiz“: Gießener Forscher tüfteln an neuem Antibiotika-Wirkstoff

  Gießener Allgemeine | Forscher aus Gießen arbeiten seit geraumer Zeit an einem neuen Antibiotika-Wirkstoff. Ein Blick hinter die Kulissen einer spannenden Entwicklung, die weit über die Naturwissenschaft hinausgeht.

  Full Story